Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOGETHER Trial: Fluvoxamine, Fluoxetine, Budesonide, and Spirulina in Mild COVID-19
NCT04727424Phase 3Recruiting
- Sponsor
- CardResearch
- Start
- Jan 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fluvoxamine, EPI-EE, fluoxetine, spirulina in coronavirus disease 2019 (COVID-19), sponsored by CardResearch. Started Jan 2021; status: recruiting.
02
Drugs
fluvoxamineEPI-EEfluoxetinespirulina
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04727424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04727424.